Search results for "immunophenotyping"

showing 10 items of 175 documents

Characterization of Human γδ T Lymphocytes Infiltrating Primary Malignant Melanomas

2012

T lymphocytes are often induced naturally in melanoma patients and infiltrate tumors. Given that gamma delta T cells mediate antigen-specific killing of tumor cells, we studied the representation and the in vitro cytokine production and cytotoxic activity of tumor infiltrating gamma delta T cells from 74 patients with primary melanoma. We found that gamma delta T cells represent the major lymphocyte population infiltrating melanoma, and both V delta 1(+) and V delta 2(+) cells are involved. The majority of melanoma-infiltrating gamma delta cells showed effector memory and terminally-differentiated phenotypes and, accordingly, polyclonal gamma delta T cell lines obtained from tumor-infiltrat…

MelanomasCytotoxicity ImmunologicMaleRENAL-CELL CARCINOMA OVERCOMING IMMUNOLOGICAL-TOLERANCE METASTATIC MELANOMA TUMOR-CELLS PHASE-I MEVALONATE PATHWAY TARGETING CTLA-4 LYMPH-NODES IMMUNOTHERAPY CANCERAnatomy and PhysiologySkin NeoplasmsTUMOR-CELLSLymphocytemedicine.medical_treatmentT-LymphocytesSettore MED/19 - Chirurgia PlasticaTARGETING CTLA-4Interleukin 21T-Lymphocyte SubsetsImmune PhysiologyMETASTATIC MELANOMACytotoxic T cellIL-2 receptorSkin TumorsMelanomaOVERCOMING IMMUNOLOGICAL-TOLERANCEAged 80 and overMultidisciplinaryT CellsMelanomaMalignant MelanomaQRReceptors Antigen T-Cell gamma-deltaMiddle AgedCANCERPHASE-Imedicine.anatomical_structureCytokinePhenotypeOncologyCytokinesMedicineFemaleResearch ArticleTumor ImmunologyAdultScienceT cellImmune CellsImmunologyMalignant Skin NeoplasmsDermatologyBiologyImmunophenotypingImmune systemLymphocytes Tumor-InfiltratingmedicineHumansIMMUNOTHERAPYBiologyAgedNeoplasm StagingSettore MED/04 - Patologia GeneraleLYMPH-NODESCancers and NeoplasmsImmunologic Subspecialtiesmedicine.diseaseImmune SystemImmunologyOVERCOMING IMMUNOLOGICAL-TOLERANCE; METASTATIC MELANOMA; TUMOR-CELLS; PHASE-I; MEVALONATE PATHWAY; TARGETING CTLA-4; LYMPH-NODES; IMMUNOTHERAPY; CANCERClinical ImmunologyImmunologic MemoryMEVALONATE PATHWAYPLoS ONE
researchProduct

A Rare Presentation of Mycosis Fungoides Mimicking Psoriasis Vulgaris

2009

Mycosis fungoides (MF) is an uncommon primary cutaneous lymphoma with a wide spectrum of clinicopathological manifestations. Diagnosis can be difficult in its early stages given the considerable overlap with more common benign dermatoses. We report an unusual case of MF in a 52-year-old male presenting with psoriasiform plaques on the palms and the soles who rapidly developed additional lesions on the scalp, limps and trunk. Punch biopsy of the face was obtained for routine histology and immunohistochemical stains. Chest X-ray, total body computed tomography scanning and excisional biopsy of the inguinal lymph node were performed. Review of the face biopsy revealed a diffuse dermal infiltra…

Mycosis fungoidesMycosis fungoidesPathologymedicine.medical_specialtyAtypical LymphocyteMycosis fungoides Cutaneous lymphoma Psoriasismedicine.diagnostic_testbusiness.industryHistologyDermatologylcsh:RL1-803medicine.diseaseDermatologyCutaneous lymphomamedicine.anatomical_structureImmunophenotypingCutaneous lymphomaPsoriasisScalpBiopsymedicinelcsh:DermatologyCase Reports in DematologyPsoriasisbusinessCase Reports in Dermatology
researchProduct

Characterization of neutrophil subsets in healthy human pregnancies

2014

We have previously shown that in successful pregnancies increased arginase activity is a mechanism that contributes to the suppression of the maternal immune system. We identified the main type of arginase-expressing cells as a population of activated low-density granulocytes (LDGs) in peripheral blood mononuclear cells and in term placentae. In the present study, we analyzed the phenotype of LDGs and compared it to the phenotype of normal density granulocytes (NDGs) in maternal peripheral blood, placental biopsies and cord blood. Our data reveal that only LDGs but no NDGs could be detected in placental biopsies. Phenotypically, NDGs and LDGs from both maternal and cord blood expressed diff…

NeutrophilsPlacentaEnzyme Metabolismlcsh:MedicineGene ExpressionBiochemistryCell DegranulationNeutrophil ActivationImmune toleranceLeukocyte Count0302 clinical medicineImmunophenotypingPregnancyMolecular Cell BiologySUPPRESSOR-CELLSlcsh:Science0303 health scienceseducation.field_of_studyMultidisciplinaryL-ARGININEObstetrics and GynecologyFetal BloodInnate Immunity3. Good healthEnzymesmedicine.anatomical_structurePhenotypeARGINASE ACTIVITYCord bloodMedicineScience & Technology - Other TopicsFemaleBiological MarkersTHERAPEUTIC PERSPECTIVESResearch ArticleEXPRESSIONAdultCordGeneral Science & TechnologyImmune CellsPopulationImmunologyBiologyMETABOLISMGRANULOCYTESGPI-Linked ProteinsPeripheral blood mononuclear cellMECHANISMSImmunophenotyping03 medical and health sciencesImmune systemAntigens CDPlacentaMD MultidisciplinarymedicineImmune ToleranceHumansCell LineageeducationBiology030304 developmental biologyScience & TechnologyArginaseMULTIDISCIPLINARY SCIENCESlcsh:RImmunityOXIDANT RELEASEImmunologyWomen's Healthlcsh:QClinical ImmunologyIMMUNE-SYSTEMCell Adhesion MoleculesCytometryBiomarkers030215 immunology
researchProduct

PSA Depletion Induces the Differentiation of Immature Neurons in the Piriform Cortex of Adult Mice

2021

Immature neurons are maintained in cortical regions of the adult mammalian brain. In rodents, many of these immature neurons can be identified in the piriform cortex based on their high expression of early neuronal markers, such as doublecortin (DCX) and the polysialylated form of the neural cell adhesion molecule (PSA-NCAM). This molecule plays critical roles in different neurodevelopmental events. Taking advantage of a DCX-CreERT2/Flox-EGFP reporter mice, we investigated the impact of targeted PSA enzymatic depletion in the piriform cortex on the fate of immature neurons. We report here that the removal of PSA accelerated the final development of immature neurons. This was revealed by a h…

Olfactory systemMaleDendritic spineDoublecortin ProteinGlycoside HydrolasesQH301-705.5PSA-NCAMneuronal precursorsNeural Cell Adhesion Molecule L1Piriform CortexSynaptic TransmissionCatalysisArticleImmunophenotypingInorganic ChemistryMiceneuronal maturationGenes ReporterdoublecortinPiriform cortexAnimalsPhysical and Theoretical ChemistryBiology (General)olfactory cortexMolecular BiologyQD1-999SpectroscopyNeuronsbiologyOrganic ChemistryCell DifferentiationGeneral MedicineAxon initial segmentComputer Science ApplicationsCell biologyDoublecortinChemistryNeuronal circuitsnervous systembiology.proteinSialic AcidsNeural cell adhesion moleculeNeuNBiomarkersInternational Journal of Molecular Sciences
researchProduct

Immunophenotype based on inflammatory cells, PD-1/PD-L1 signalling pathway and M2 macrophages predicts survival in gastric cancer

2020

Abstract Background Immune response against cancer has prognostic impact but its role in gastric cancer is poorly known. The aim of the study was to assess the prognostic significance of immune cell score (CD3+, CD8+), tumour immune escape (PD-L1, PD-1) and immune tolerance (Clever-1). Methods After exclusion of Epstein-Barr virus positive (n = 4) and microsatellite instable (n = 6) tumours, the study included 122 patients with GC undergoing D2 gastrectomy. CD3+ and CD8+ based ICS, PD-L1, PD-1 and Clever-1 expressions were evaluated. Differences in survival were examined using Cox regression adjusted for confounders. The primary outcome was 5-year survival. Results The 5-year overall surviv…

OncologyAdultMaleCancer Researchmedicine.medical_specialtyProgrammed Cell Death 1 ReceptorAdenocarcinomaArticleB7-H1 AntigenImmune toleranceImmunophenotyping03 medical and health sciences0302 clinical medicineImmunophenotypingImmune systemStomach NeoplasmsInternal medicinePD-L1medicineImmune ToleranceHumansAgedbiologyMolecular medicinebusiness.industryProportional hazards modelMacrophagesConfoundingImmunosurveillancemahasyöpäCancerennusteetMiddle Agedmedicine.diseaseOncologyimmuunivaste030220 oncology & carcinogenesisbiology.proteinsyöpätauditfenotyyppiFemaleTumor EscapebusinessCD8Signal TransductionBritish Journal of Cancer
researchProduct

Old and new immunophenotypic markers in multiple myeloma for discrimination of responding and relapsing patients: The importance of “normal” residual…

2015

Background Multiple myeloma is an incurable disease characterized by proliferation of clonal malignant plasma cells (CPCs), which can be immunophenotypically distinguished from polyclonal plasma cells (PPCs) by multiparameter flow cytometry (MFC). The utility of PPCs analysis in detecting prognostic and predictive information is still a matter of debate. Methods: we tested the ability of 11 MFC markers in detecting differences in the immunophenotype of CPCs and PPCs among patients in various disease stages; we verified if these markers could be associated with disease stage/response to therapy despite the role of clinical parameters. Results: significant changes in the expression of markers…

OncologyCD20Prognostic variablemedicine.medical_specialtyPathologyHistologybiologybusiness.industryCD58Cell BiologyPlasma cellmedicine.diseasePathology and Forensic Medicinemedicine.anatomical_structureImmunophenotypingInternal medicinemedicinebiology.proteinStage (cooking)businessCytometryMultiple myelomaCytometry Part B: Clinical Cytometry
researchProduct

Incidence, survival and prevalence of myeloid malignancies in Europe.

2012

Abstract Background The Surveillance of Rare Cancers in Europe (RARECARE) project aims at increasing knowledge of rare cancers in Europe. This manuscript describes the epidemiology of myeloid malignancies (MMs), taking into account the morphological characterisation of these tumours. Methods We used data gathered by RARECARE on cancer patients diagnosed from 1995 to 2002 and archived in 64 European population-based cancer registries, followed up to 31st December 2003 or later. Results The overall annual crude incidence of MMs was 8.6 per 100,000. Acute myeloid leukaemia (AML) and myeloproliferative neoplasms (MPN) were most common, with incidence rates of 3.7 and 3.1 per 100,000 year respec…

OncologyMyeloidMaleCancer ResearchMyeloidSurvivalChronic myelomonocytic leukaemiaCancer registry Incidence Prevalence Survival Myeloid malignancies Acute myeloid leukaemia Myelodysplastic syndrome Chronic myeloid leukaemia Chronic myelomonocytic leukaemiaImmunophenotypingEpidemiologyPrevalenceChildLeukemiaIncidence (epidemiology)IncidenceMyeloid malignanciesCancer registryMiddle AgedEuropeLeukemia Myeloid AcuteLeukemiamedicine.anatomical_structureOncologyChild PreschoolMyelodysplastic-Myeloproliferative Diseases/epidemiology/mortalityMyelodysplastic Syndromes/epidemiology/mortalityFemaleAdultmedicine.medical_specialtyAdolescentAcute myeloid leukaemiaNOEurope/epidemiologyInternal medicinemedicinecancer Incidence; survival and prevalence; myeloid malignanciesHumansPreschoolChronic myeloid leukaemiaddc:613AgedMyeloproliferative Disorders/epidemiology/mortalityMyeloproliferative Disordersbusiness.industryMyelodysplastic syndromesInfant NewbornCancerInfantcancer Incidencemedicine.diseaseNewbornMyelodysplastic-Myeloproliferative DiseasesCancer registrysurvival and prevalenceMyelodysplastic SyndromesImmunologyAcute/epidemiology/mortalitybusinessMyelodysplastic syndrome
researchProduct

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

2017

Abstract The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults, published in 2010, has found broad acceptance by physicians and investigators caring for patients with AML. Recent advances, for example, in the discovery of the genomic landscape of the disease, in the development of assays for genetic testing and for detecting minimal residual disease (MRD), as well as in the development of novel antileukemic agents, prompted an international panel to provide updated evidence- and expert opinion-based recommendations. The recommendations include a revised version of the ELN genetic categories, a proposal for …

PathologyNeoplasm ResidualInternational CooperationDiseaseReview ArticleBiochemistryEuropean LeukemiaNet0302 clinical medicineRisk Factorshemic and lymphatic diseasesCONVENTIONAL CARE REGIMENSDisease management (health)medicine.diagnostic_testACUTE MYELOGENOUS LEUKEMIAHematopoietic Stem Cell TransplantationDisease ManagementSINGLE CEBPA MUTATIONSHematology1ST COMPLETE REMISSIONHIGH-DOSE CYTARABINELeukemia Myeloid AcuteTreatment Outcome030220 oncology & carcinogenesisPractice Guidelines as TopicAdultmedicine.medical_specialtyConsensusImmunologyBUSULFAN PLUS CYCLOPHOSPHAMIDEMEDLINEMINIMAL RESIDUAL DISEASEAntineoplastic AgentsACUTE MYELOID-LEUKEMIAEnasidenibTransplantation AutologousDrug Administration ScheduleImmunophenotyping03 medical and health sciencesmedicineHumansGenetic TestingIntensive care medicineGenetic testingbusiness.industrySTEM-CELL TRANSPLANTATIONCell BiologyRANDOMIZED PHASE-IIIMinimal residual diseaseTransplantationbusinessSettore MED/15 - Malattie del Sangue030215 immunology
researchProduct

Correlation between CD117+ myeloma plasma cells and hematopoietic progenitor cells in different categories of patients

2015

Background Multiple myeloma (MM) is a neoplastic disorder of plasma cells interesting mainly the elderly. MM remains an incurable disease, mostly because of the strong interplay between clonal plasma cells (cPCs) and bone marrow (BM) microenvironment. Multiparameter flow cytometry (MFC) allows the simultaneous study of the cPC immunophenotype and alterations involving other cells in BM, but rarely these data are interpreted as connected. One exception to this habit are previous studies about relationship between CD117 cPC positivity and hematopoietic progenitor cell (HPC) distribution in newly diagnosed patients. Thus we were interested in verifying the distribution of BM CD34+ HPCs in heal…

Pathologymedicine.medical_specialtyAgingImmunologyCD34CD117ImmunophenotypingCD117; Flow cytometry; Hematopoietic progenitor cell; MGUS; Multiple myeloma; Immunology; AgingMultiple myelomamedicineHematopoietic progenitor cellFlow cytometryMultiple myelomaSettore MED/04 - Patologia GeneralebiologyCD117business.industryResearchmedicine.diseasedigestive system diseasesAgeingmedicine.anatomical_structurebiology.proteinMGUSBone marrowAntibodybusinessProgressive diseaseMonoclonal gammopathy of undetermined significance
researchProduct

Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases

2015

Background Multiparameter flow cytometry (MFC) identification and characterization of plasma cells (PCs) is a useful tool to support diagnosis, prognostication, and monitoring of PC diseases (PCD). Currently, the number of MFC markers suited for the identification of PC remains limited. Moreover, antibody therapies against PC-associated markers further compromise the utility of the most widely used reagents (e.g., CD38). Despite markers other than CD38 and CD138 are recognized as potentially useful PC-identification markers, no study has comparatively evaluated their performance in combination with CD38 and CD138. Here we compared the utility of CD229, CD54, and CD319 for the identification…

Pathologymedicine.medical_specialtyHistologymedicine.diagnostic_testCell BiologyBiologyPlasma cellmedicine.diseaseMinimal residual diseasePathology and Forensic MedicineFlow cytometry03 medical and health sciences0302 clinical medicineImmunophenotypingmedicine.anatomical_structureimmune system diseasesEuroFlowhemic and lymphatic diseases030220 oncology & carcinogenesismedicineBone marrowCytometryMultiple myeloma030215 immunologyCytometry Part B: Clinical Cytometry
researchProduct